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Hypergammaglobulinemia is often found in patients with autoimmune diseases such as 
systemic lupus erythematosus (SLE), and its level may correlate with disease activity.  
However, it is unclear whether IgG displays seasonal changes. We analyzed the seasonal 
change in serum IgG using 450 connective tissue disease patients.  The serum IgG 
levels in summer were compared with those in winter from 2006 to 2009.  Independent 
samples from 355 patients were analyzed to confirm results in the first set. The 
differences in the IgG levels between the two seasons were analyzed in each disease and 
compared with disease activity. 488 patients without connective tissue disease were 
analyzed as reference instead of healthy people as control. We found that connective 
tissue disease patients tended to show higher levels of serum IgG in summer than in 
winter every year from 2006 to 2009, while patients without connective tissue disease 
did not demonstrate such a tendency.  We observed this seasonal tendency in each 
disease.  Seasonal changes of serum IgG weakly correlated with those of anti-DNA 
antibody in SLE patients and those of disease activity score in rheumatoid arthritis 
patients. The serum IgG levels of patients with connective tissue diseases display 
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IgG are a major fraction of immunoglobulins produced by plasma cells in lymphoid 
organs that comprise ~20% of serum proteins. IgG bind to antigens to induce an 
inflammatory response or form immune complexes [1].  It is widely known that 
patients with connective tissue diseases, especially those with Sjögren’s syndrome (SS), 
systemic lupus erythematosus (SLE), or mixed connective tissue disease (MCTD), 
display hypergammaglobulinemia or a high IgG titer.  IgG is used to evaluate the 
effects of immunosuppressive therapy, and some autoantibody titers are known to be 
related to disease activity, for example, anti-double strand DNA antibody titers are 
related to lupus nephritis and its activity [2-4], and a previous report demonstrated that 
the IgG level is associated with lymphoid infiltration in SS [5].  However, the effects 
of seasonal changes in the IgG levels of patients with connective tissue diseases have 
never been considered.  During our daily medical practice, we have noticed that 
connective tissue diseases patients show seasonal changes in their IgG levels regardless 
of their medication; therefore, we conducted a retrospective chart review of a large 
number of connective tissue diseases patients at our hospital to verify our hypothesis. 
 
Materials and Methods 
 
Cases and controls 
 450 Patients with connective tissue diseases who were followed-up at Kyoto 
University Hospital for whom both summer (July and August) and winter (January and 
February) IgG measurements were available for the period from 2006 to 2009 were 
enrolled in this study. They included 195 rheumatoid arthritis (RA), 140 SLE, 46 
Systemic Sclerosis (SSc), 19 MCTD, 41 primary SS, and 28 
Polymyositis/Dermatomyositis (PM/DM) patients. Independent 355 patients with 
connective tissue diseases followed-up at Kyoto University were analyzed as the 
replication of the results in the first set. They included 155 RA, 123 SLE, 33 SSc, 13 
MCTD, 32 primary SS, and 23 PM/DM patients. A fraction of patients had more than 
two connective tissue diseases and overlapping in more than two disease subgroups was 
allowed. We extracted 488 patients without connective tissue diseases whose IgG data 
were available from 39,089 outpatients at Kyoto University Hospital on January and 
February in 2010 and analyzed them as reference instead of healthy people as control. 
Basic information of each group was shown in Table 1. Connective tissue diseases 
patients fulfilled the criteria of each disease, namely, ACR criteria for RA[6], SLE[7], 




































































and DM[11].  This study was designed in accordance with Helsinki Declaration and 
granted by Kyoto University Graduate School and Faculty of Medicine, Ethics 
Committee. Information of this study is disclosed to all the patients instead of obtaining 
written informed consent. 
 
IgG levels and disease markers 
A retrospective chart review of the enrolled patients was performed to evaluate 
their serum IgG levels from 2006 to 2009.  We obtained disease activity score (DAS) 
28 in patients with RA and titers of serum C3, C4, CH50, anti-DNA antibody, and urine 
protein in patients with SLE from 2006 to 2009. We used data of these markers which 
were evaluated on the same date as evaluation of IgG.  
 
Statistical analyses 
 The serum IgG levels in summer were compared with those in winter for each 
patient from 2006 to 2009. The difference between the two seasons was defined as ΔIgG 
(ΔIgG =IgGsummer - IgGwinter). The ratio value of positive ΔIgG in each group for 
each year was compared with the null hypothesis that the ratio is not different from 50% 
in binomial test.  Logistic regression analyses were used to adjust other factors such as 
age, sex, and treatment.  Statistical analyses were performed using R software 
(http://www.r-project.org/) or SPSS (version 18).  
 
Results 
450 patients with connective tissue diseases were selected and had their IgG 
levels evaluated in a retrospective manner from 2006 to 2009.  The connective tissue 
disease patients showed higher IgG levels in summer than in winter in 2009 (p=0.00070, 
Table 2). This tendency was kept in other 3 years (Table 2).  To confirm these results, 
we evaluated another independent set containing 355 connective tissue disease patients 
who were followed-up around the same time as the first set.  The second set also 
showed that the connective tissue disease patients had higher IgG levels in summer than 
in winter in all the four years (Table 2).  When we combined the two datasets, the ratio 
of positive ΔIgG in the connective tissue disease patients reached significant level in 
2006, 2007, and 2009 (Table 2). Although the ratio did not show significant p-value in 
2008, the tendency was kept in 2008 (Table 2). Especially SLE within connective tissue 
diseases demonstrated high ratio value of positive ΔIgG (Table 2).   
As we could not obtain the successive serum IgG data from healthy people, we used 




































































IgG seasonal change found in connective tissue disease was observed in general.  As a 
result, we could not find any regular tendency of ratio value of positive ΔIgG in this 
group (Table 2).  Logistic regression analysis using these patients and connective 
tissue disease patients demonstrated that the positive ΔIgG was associated with to have 
connective tissue diseases even after adjustment by serum IgG levels at baseline, age, 
sex, and treatment (Table 3).  
Next we analyzed the data with stringent cut off (ΔIgG >10mg/dl as positive 
change and -10mg/dl >ΔIgG as negative change) to exclude the possibility that just 
subtle seasonal movement of serum IgG level greatly influenced on the overall ratio 
value of positive ΔIgG. There is a possibility that change of temperature, humidity and 
so on between the seasons may influence on machinery to cause subtle change.  We 
observed the same tendency of IgG movement even with stringent cutoff in connective 
tissue diseases and each connective tissue disease subgroup (Supplementary Table 1). 
The reference group did not show a regular tendency.  When we set more stringent cut 
off (ΔIgG >100mg/dl as positive change and -100mg/dl >ΔIgG as negative change), we 
observed the same results in all groups (Supplementary Table 2). From these, we 
concluded that the seasonal variations of serum IgG we found in the current study were 
not due to some kinds of errors in machinery or sampling bias. 
As the SLE subgroup shows clear seasonal variations of serum IgG among 
connective tissue diseases and it is a large part of patients with connective tissue 
diseases in this study, we chose the SLE patients to assess the correlation of ΔIgG with 
disease activity. The successive data of anti-DNA antibody, C3, C4, CH50, and urine 
protein were obtained for the SLE patients. We compared the changes of these markers 
for SLE activity with ΔIgG in the patients. While we could not observe meaningful 
association between ΔIgG and seasonal change of C3, C4, CH50 or urine protein, we 
found that ΔIgG was moderately correlated with the seasonal change of anti-DNA 
antibody in 2009 (rho(Spearman’s rank-sum coefficient)=0.35, p=1.6x10-5).  We found 
that this correlation was kept in other three years (rho is 0.30 or larger). Even when we 
chose SLE patients demonstrating a stringent changes of anti-DNA antibody 
(Δanti-DNA >=5 IU/ml or -5 IU/ml>=Δanti-DNA), we observed rather strong 
correlation between the two markers in 2009 (rho=0.47, p=0.013, Figure 1a).  We 
found that this tendency was also seen in other three years (rho is 0.52 or larger). 
Next we obtained DAS28 score of 40 RA patients in 2009, the standard 
measurement to evaluate clinical activity of RA, and analyzed whether ΔIgG correlated 
with the change of DAS28 or not. We detected moderate correlation between them 




































































is 0.28 or larger). 
 
Discussion 
It is widely known that many autoimmune diseases are associated with 
hypergammaglobulinemia mainly consisting of IgG.  In some diseases, 
hypergammaglobulinemia has been suggested to be associated with disease activity, 
such as lymphoid cell infiltration, treatment responsiveness, and pulmonary arterial 
hypertension in SS [5, 12]. Another previous report stated that 
hypergammaglobulinemia in children presenting with SLE-like symptoms is a 
predictive factor for developing MCTD [13].  However, no previous reports have 
evaluated the seasonal change in IgG on a large scale.  Here, we showed that more 
than half of patients with connective tissue diseases demonstrated higher IgG levels in 
summer than in winter and that some of the seasonal variations may correlate with 
disease activity to some extent. 
When we focus on patients with connective tissue diseases whose IgG data 
were frequently measured to determine two seasons to compare in the preliminary study, 
the movement of their IgG titers throughout the year suggested that IgG levels in spring 
and autumn are between the levels in summer and winter (data not shown). This 
indicates that our comparison between the two seasons in the current study is enough to 
assess seasonal variation of serum IgG.  Moreover, to compare specific two seasons 
seems good to avoid multiple testing which increases type 1 error of the statistics.  
In this study, we analyzed two independent set of samples with connective 
tissue diseases and found that this tendency of seasonal variation of IgG levels was kept 
for all the four years.  We observed this tendency in each connective tissue disease and 
in patients with SLE in particular. As we could not obtain IgG data for healthy people, 
we used data from 488 patients without connective tissue diseases as reference. They 
have variable diseases from variable departments, such as eczema, IgA nephropathy, 
HTLV-1 infection, and malignant lymphoma.  As a result, they did not show a regular 
tendency.  Although it’s much better to use data from age and sex-matched healthy 
people as control, the result obtained from reference group suggests that the seasonal 
change of serum IgG levels is not seen in general. Moreover, the logistic regression 
analysis did not significantly alter the association between seasonal variation of IgG and 
connective tissue diseases, even with adjustment by age, sex, treatment, and serum IgG 
level at baseline. When these variations were mainly comprised by very small variations 
of IgG such as less than 10 mg/dl, some might argue that they are not fully convincing.  




































































stringent cut offs for seasonal variation of serum IgG level, we still observed seasonal 
changes of serum IgG in connective tissue diseases and its subgroups. This denied the 
possibility of our results being affected by some tiny changes of IgG levels due to 
machinery errors between the two seasons.  
To analyze the biological meaning of its seasonal change, we compared ΔIgG 
with changes of levels of anti-DNA antibody, complement, and urine protein in patients 
with SLE and those of DAS28 in patients with RA. We found that ΔIgG weakly 
correlated with changes of serum anti-DNA antibody in SLE patients and with those of 
DAS28 in RA patients. Because anti-DNA antibody is a fraction of IgG, it is reasonable 
for them to correlate with each other to some extent. However, it is interesting that ΔIgG 
strongly correlate with stringent change of anti-DNA antibody. These results suggest 
that ΔIgG reflect changes of disease activity in some fraction of patients with 
connective tissue diseases, although further analysis is necessary. 
Seasonal effects on the onset, relapse, and disease activity of some connective 
tissue diseases have been reported.  In general, SLE activity is believed to increase in 
spring and summer due to sunlight exposure [14].  However, there are also conflicting 
reports showing no seasonal change in lupus activity [15-16]. The influence of season 
on PM/DM is also disputed [17-18].  Therefore, it does not seem that the seasonal IgG 
changes seen in connective tissue diseases patients are solely due to disease activity.  It 
is possible that the use of additional medications including immunosuppressants or 
corticosteroids to suppress disease flare-up in winter affected our results. However, 
logistic regression analysis did not alter the association after adjustment of treatment. 
Moreover, patients with primary SS, in whom immunosuppressants or corticosteroids 
are scarcely used, also showed the same tendency, suggesting that this possibility cannot 
fully explain the phenomena.   
The IgG change in the connective tissue diseases patients seemed to be 
proportional to the temperature throughout the year, but it is unlikely that the change in 
IgG is caused by temperature changes because the reference group did not show a 
similar tendency.  When we compared the IgG level with the mean temperature in 
Kyoto, the correlation between them was highly variable from patient to patient (data 
not shown).  
The difference between the patients with connective tissue diseases and those 
without them might reflect a difference in B cell function between the two groups.  To 
elucidate whether other immunoglobulin fractions act in the same manner as IgG, we 
analyzed IgA and IgM in a similar manner.  However, we could not find any regular 




































































disease patients (data not shown).  
We do not know the underlying mechanisms of this IgG change in connective 
tissue disease patients. Further analysis should be performed to address this question. To 
investigate whether this change is related to temperature, it would be interesting and 
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Correlation between ΔIgG and variation of disease activity in SLE and RA. 
Seasonal variation of serum IgG levels was compared with that of anti-DNA antibody in 
27 SLE patients (a) or that of DAS28 in 40 RA patients (b). The results in 2009 were 







































































Table 1. Basic information of patients 
 
Connective tissue disease 
 
















































































































Table 2. Ratio of patients in each year whose serum IgG levels are higher in summer than in winter. 
 
2006 2007 2008 2009 
 
























60.6(53.1-68.2) 55.2(48.6-61.8) 54.5(48.6-60.4) 61(55.2-66.8) 































































































































 51.4(43.3-59.4) 52.3(45.3-59.2) 48(42.1-53.9) 47.5(41.9-53.0) 
Seasonal change of serum IgG in patients with connective tissue diseases and patients without connective tissue diseases as reference 
was shown. Patients whose data of IgG change were available were analyzed in each year. While the results in patients with connective 
tissue diseases in the first set, second set, and combined sets were indicated, those in patients with each connective tissue disease in the 
combined sets were shown. Positive ratio indicates a ratio value of patients whose IgG levels were higher in summer than in winter in 
each year. When a patient had more than two connective tissue diseases, overlapping in more than two groups was allowed. 


























































IgG in winter* 0.021 0.97(0.95-1.00) 
ICS** 0.66 0.93(0.66-1.30) 
Corticosteroid 0.50 0.91(0.67-1.22) 
Connective Tissue Disease 0.0078 1.58(1.12-2.23) 
Age 0.94 1.00(0.99-1.01) 
Female 0.043 1.42(1.00-2.00) 
Logistic regression analysis was performed using positive ΔIgG as a dependent variable 
and IgG in winter, usage of immunosuppressant or corticosteroid, having connective 
tissue diseases, age, and sex as independent variables. The results in 2009 using the data 
of 618 patients with connective tissue diseases and 314 patients without connective 
tissue diseases were shown as a representative. 
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